Erfan Bashar
Back to Cerebral Amyloid Angiopathy

Cerebral Amyloid Angiopathy — Treatment

~2 min read
Last medically reviewed:
On this pageTable of contents

Educational scope notice: This is a study note for medical students, not medical advice, diagnosis, or treatment guidance. Clinical management should follow local protocols and current guidelines.

There is no disease-modifying therapy for amyloid angiopathy. Management is entirely about preventing the next haemorrhage, and every decision is shaped by how fragile the affected vessels are.

Avoiding antithrombotics

Antiplatelet agents and anticoagulants raise the bleeding risk from amyloid-laden vessels, and an anticoagulated microbleed can become a catastrophic lobar haemorrhage. They are therefore generally avoided once probable disease is established. The difficult case is coexistence with atrial fibrillation or vascular disease, where a thrombotic risk also demands attention. That decision is individualised, weighing stroke risk against haemorrhage risk, with the microbleed burden on blood-sensitive MRI informing the bleeding side of the scale.

Blood pressure control

Tight blood pressure management reduces the mechanical stress on fragile vessels and is the main modifiable measure against rebleeding, following standard post-haemorrhage secondary-prevention guidance. Acute hypertensive episodes can precipitate rupture, so both long-term control and avoidance of sharp rises matter.

Surgical considerations

Evacuation of a lobar haematoma follows standard intracerebral haemorrhage decision-making by location, size, and consciousness level. The surrounding tissue in amyloid angiopathy is itself diseased, which raises the risk of perioperative rebleeding. Tissue biopsy is rarely performed but can establish pathology-supported diagnostic certainty where management truly depends on it.

Anti-amyloid antibodies and ARIA

Anti-amyloid antibodies for Alzheimer disease, such as lecanemab, mobilise amyloid that is also present in vessel walls. They carry a risk of amyloid-related imaging abnormalities (ARIA): oedema or effusion type (ARIA-E) and haemorrhage type including microbleeds and superficial siderosis (ARIA-H).

Patients with amyloid angiopathy or a substantial baseline haemorrhagic lesion burden face higher ARIA risk, so MRI screening for such lesions is required before starting treatment, and extensive CAA-type findings weigh against it.

Evidence anchors

Suggest a correction